Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW INDICATIONS

On August 24, 2022, the FDA accelerated the approval of ibrutinib (Imbruvica; Pharmacyclics), a Bruton tyrosine kinase inhibitor, for chronic graft-versus-host disease (GVHD) in pediatric patients aged ≥1 year whose disease did not respond to ≥1 lines of systemic therapy. Concomitantly, the FDA approved a new oral suspension formulation of ibrutinib for use in this patient population.

Ibrutinib was previously approved for adults with chronic GVHD, marginal-zone lymphoma, Waldenström’s macroglobulinemia, chronic or small lymphocytic leukemia, and mantle-cell lymphoma.

The new indication was based on results of the open-label, multicenter, single-arm iMAGINE trial of 47 pediatric patients and young adults aged 1 year to <22 years with moderate or severe chronic GVHD who required additional treatment after ≥1 systemic therapies.

The main end point was overall response rate (ORR) through week 25. The ORR was 60% (95% confidence interval [CI], 44-74). The median duration of response was 5.3 months (95% CI, 2.8-8.8), and the median time from first response to new systemic therapies for chronic GVHD or death was 14.8 months (95% CI, 4.6-not evaluable).

“The new Imbruvica oral suspension formulation helps address challenges children may have with swallowing capsules or tablets,” said Paul A. Carpenter, MD, of Seattle Children’s Hospital, and a study investigator.

The most common (≥20%) adverse events were anemia, musculoskeletal pain, pyrexia, diarrhea, pneumonia, abdominal pain, stomatitis, thrombocytopenia, and headache.

Related Items
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.